Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500301 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Testing to Personalize Supportive Oncology
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT04500301 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants.
The verdict
NCT04500301, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer. The investigators aim to understand how PGx testing can be used to improve medication management for pain and depression, and whether PGx-guided prescribing improves these symptoms and quality of life compared to historical controls.
Interventions
- OTHER Preemptive Pharmacogenomic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2023-12-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04500301
The ClinicalTrials.gov registry entry for NCT04500301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Preemptive Pharmacogenomic Testing is the first listed.
NCT04500301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04500301 about?
NCT04500301 is a clinical study titled "Pharmacogenomic Testing to Personalize Supportive Oncology". The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer. The investigators aim to understand how PGx testing can be used to improve medication management for pain and depression, and whether PGx-guided prescribing improv...
What is the current status of trial NCT04500301?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2020-12-02. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT04500301?
The interventions under investigation include: Preemptive Pharmacogenomic Testing (OTHER).
Who is sponsoring clinical trial NCT04500301?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.